CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $363,678
- in 3 filings, $327K under 10b5-1 plans
Net −$363,678. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-03 | Ho Carole Chief Medical Officer | Grant or award | +41,120 | 138,967 | ||
| 2023-01-03 | Ho Carole Chief Medical Officer | Grant or award · Stock Option (right to buy) | +123,360 | 123,360 | ||
| 2023-01-03 | Schuth Alexander O. COFO and Secretary | Grant or award | +41,120 | 157,578 | ||
| 2023-01-03 | Schuth Alexander O. COFO and Secretary | Grant or award · Stock Option (right to buy) | +123,360 | 123,360 | ||
| 2023-01-03 | Watts Ryan J. President and CEO | Grant or award | +82,240 | 231,934 | ||
| 2023-01-03 | Watts Ryan J. President and CEO | Grant or award · Stock Option (right to buy) | +246,720 | 246,720 | ||
| 2022-11-23 | Tessier-Lavigne Marc Director | Sale | −20,000 | $30.48 | $610K | 1,870,356 |
| 2022-11-02 | Tessier-Lavigne Marc Director | Sale | −11,252 | $30.33 | $341K | 1,890,356 |
| 2022-11-01 | Tessier-Lavigne Marc Director | Sale | −8,748 | $30.20 | $264K | 1,901,608 |
| 2022-10-07 | Schuth Alexander O. COFO and Secretary | Option exercise | +20,000 | $0.68 | $14K | 487,471 |
| 2022-10-07 | Schuth Alexander O. COFO and Secretary | Option exercise · Stock Option (right to buy) | −20,000 | 220,078 | ||
| 2022-09-28 | Tessier-Lavigne Marc Director | Sale | −15,577 | $30.74 | $479K | 1,914,779 |
| 2022-09-28 | Tessier-Lavigne Marc Director | Sale | −4,423 | $31.08 | $137K | 1,910,356 |
| 2022-08-23 | Tessier-Lavigne Marc Director | Sale | −19,900 | $31.61 | $629K | 1,930,456 |
| 2022-08-23 | Tessier-Lavigne Marc Director | Sale | −100 | $32.43 | $3K | 1,930,356 |
| 2022-08-23 | Ho Carole Chief Medical Officer | Sale | −2,424 | $31.98 | $78K | 170,663 |
| 2022-08-19 | Watts Ryan J. President and CEO | Sale | −2,404 | $33.22 | $80K | 2,202,993 |
| 2022-08-19 | Krognes Steve E. Director | Sale | −2,253 | $33.22 | $75K | 149,468 |
| 2022-08-19 | Schuth Alexander O. COFO and Secretary | Sale | −2,576 | $33.22 | $86K | 467,471 |
| 2022-08-19 | Ho Carole Chief Medical Officer | Sale | −2,576 | $33.22 | $86K | 173,087 |
Page 14 of 53 · 1,043 trades